We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · August 15, 2022

SH-1028, a Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR T790M–Positive NSCLC

Journal of Thoracic Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Thoracic Oncology
Efficacy and Safety of SH-1028 in Patients With EGFR T790M-Positive NSCLC: A Multicenter, Single-Arm, Open-Label, Phase 2 Trial
J Thorac Oncol 2022 Jul 05;[EPub Ahead of Print], A Xiong, S Ren, H Liu, L Miao, L Wang, J Chen, W Li, R Li, X Wang, Z Lu, D Wang, X Wu, Z Liu, L Xing, Y Mao, C Liu, A Zeng, H Niu, Y Du, Y Sun, Y Pan, Y Hu, X Zhang, X Chen, Z Ma, N Li, J Zhang, M Zhao, X Li, F Ye, M Li, G Yu, X Zhang, J Min, D Han, J Li, C Zhou

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading